QHSLab (USAQ)
OTHER OTC:USAQ
Want to see USAQ full AI Analyst Report?
Top Page
QHSLab
(OTC:USAQ)
Select Model
Select Model
Rating:64Neutral
Price Target:
$0.64
▲(31.02% Upside)
Action:ReiteratedDate:04/22/26
The score is driven primarily by improved financial performance in 2025 (profitability turnaround and dramatically lower leverage), supported by positive recent corporate updates. Offsetting this, technicals remain weak-to-neutral with the stock below key moving averages, and cash conversion/turnaround durability remain key risks.
Positive Factors
Profitability Turnaround
QHSLab’s 2025 shift to positive net income and expanded gross margins signals improved unit economics and operating leverage. Sustained margins reduce insolvency risk, enable reinvestment in product and sales, and provide a stronger foundation for repeatable earnings if operational discipline continues.
Negative Factors
Weak Cash Conversion
Despite positive net income, operating cash flow trails earnings materially, indicating earnings quality and working-capital stress. Persistent weak cash conversion can force dependence on external capital, constrain investment, and make profitability fragile if receivables or reimbursements fluctuate.
Read all positive and negative factors
Positive Factors
Negative Factors
Profitability Turnaround
QHSLab’s 2025 shift to positive net income and expanded gross margins signals improved unit economics and operating leverage. Sustained margins reduce insolvency risk, enable reinvestment in product and sales, and provide a stronger foundation for repeatable earnings if operational discipline continues.
Read all positive factors
QHSLab (USAQ) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$10.20M
Dividend YieldN/A
Average Volume (3M)6.57K
Price to Earnings (P/E)15.0
Beta (1Y)0.82
Revenue Growth43.55%
EPS Growth-461.90%
CountryUS
Employees4
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.03
Shares Outstanding15,032,788
10 Day Avg. Volume9,209
30 Day Avg. Volume6,568
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)4.21
Price to Sales (P/S)2.54
P/FCF Ratio38.43
Enterprise Value/Market Cap0.75
Enterprise Value/Revenue2.84
Enterprise Value/Gross Profit4.22
Enterprise Value/Ebitda9.72
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.3
Revenue Forecast (FY)N/A
QHSLab Business Overview & Revenue Model
Company Description
QHSLab, Inc., a medical device technology and software as a service (SaaS) company, focuses on value-based healthcare, informatics, and algorithmic personalized medicine. It also develops digital therapeutics and point of care solutions to support...
How the Company Makes Money
null...
QHSLab Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
78
Positive
Cash Flow
64
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.69M | 2.13M | 1.41M | 1.24M | 1.41M |
| Gross Profit | 1.81M | 1.36M | 793.61K | 619.52K | 670.75K |
| EBITDA | 785.56K | 352.39K | -91.29K | -434.60K | -487.63K |
| Net Income | 457.42K | -259.24K | -468.36K | -996.00K | -770.18K |
Balance Sheet | |||||
| Total Assets | 2.17M | 1.80M | 1.68M | 1.96M | 2.21M |
| Cash, Cash Equivalents and Short-Term Investments | 636.16K | 157.17K | 51.58K | 178.69K | 286.86K |
| Total Debt | 20.00K | 1.72M | 1.78M | 1.68M | 1.30M |
| Total Liabilities | 546.08K | 2.41M | 2.06M | 1.88M | 1.38M |
| Stockholders Equity | 1.62M | -607.76K | -375.62K | 76.25K | 824.07K |
Cash Flow | |||||
| Free Cash Flow | 178.12K | 142.44K | -159.63K | -388.11K | -509.31K |
| Operating Cash Flow | 178.12K | 142.44K | -159.63K | -350.99K | -354.74K |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | -37.12K | -154.57K |
| Financing Cash Flow | 300.87K | -36.85K | 32.52K | 279.95K | 701.82K |
QHSLab Technical Analysis
Positive
0.49
Price Trends
0.66
Negative
0.61
Positive
0.40
Positive
Market Momentum
>-0.01
Negative
51.30
Neutral
70.18
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For USAQ, the sentiment is Positive. The current price of 0.49 is below the 20-day moving average (MA) of 0.63, below the 50-day MA of 0.66, and above the 200-day MA of 0.40, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 51.30 is Neutral, neither overbought nor oversold. The STOCH value of 70.18 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for USAQ.
QHSLab Risk Analysis
QHSLab disclosed 45 risk factors in its most recent earnings report. QHSLab reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
QHSLab Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | $10.20M | 14.96 | ― | ― | 43.55% | -461.90% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $3.69M | -0.28 | -191.39% | ― | ― | 76.53% | |
44 Neutral | $2.56M | -92.65 | -173.74% | ― | 82.96% | 82.04% | |
41 Neutral | $2.83M | -0.69 | -6046.59% | ― | -8.93% | 97.80% |
* Healthcare Sector Average
USAQ
QHSLab
0.73
0.55
314.20%
NUWE
Nuwellis
1.15
-35.43
-96.87%
AEMD
Aethlon Medical
2.29
-28.11
-92.47%
VTAK
Catheter Precision
0.96
-5.12
-84.21%
BBLG
Bone Biologics
1.41
-2.68
-65.65%
QHSLab Corporate Events
Business Operations and StrategyFinancial DisclosuresProduct-Related Announcements
QHSLab Reports Strong Q1 Growth and Launches GLP-1 Program
Positive
Apr 21, 2026
On April 21, 2026, QHSLab reported unaudited first-quarter 2026 Integrated Service Program revenue of about $370,000, up from $163,000 a year earlier, marking 127% year-over-year growth driven by expanding provider adoption of its recurring digita...
Business Operations and StrategyFinancial Disclosures
QHSLab Posts 2025 Profit, Revenue Growth and Deleveraging
Positive
Mar 31, 2026
On March 31, 2026, QHSLab reported its fiscal 2025 results, highlighting that revenue rose 26% year over year to about $2.69 million and gross margin widened to 67.3%. The company posted net income of $457,417 versus a loss in 2024, while cash cli...
Business Operations and StrategyFinancial Disclosures
QHSLab Reports 2025 Preliminary Results and Debt Reduction
Positive
Jan 26, 2026
On January 26, 2026, QHSLab reported preliminary unaudited financial results for 2025 showing revenue rose just over 25% to $2.68 million and gross profit increased more than 32% to $1.80 million, with gross margins improving from about 64% to rou...
Business Operations and StrategyPrivate Placements and Financing
QHSLab Simplifies Capital Structure With Debt-for-Equity Deal
Positive
Jan 23, 2026
QHSLab, Inc. entered into a Note Repurchase Agreement with MedScience Research Group, Inc. under which it repurchased, cancelled, and extinguished a promissory note originally issued on June 23, 2021, that had an outstanding principal and accrued ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.